Ecaterina E. Dumbrava

2.3k total citations
115 papers, 1.0k citations indexed

About

Ecaterina E. Dumbrava is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ecaterina E. Dumbrava has authored 115 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 35 papers in Cancer Research and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ecaterina E. Dumbrava's work include Cancer Genomics and Diagnostics (30 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). Ecaterina E. Dumbrava is often cited by papers focused on Cancer Genomics and Diagnostics (30 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). Ecaterina E. Dumbrava collaborates with scholars based in United States, Canada and United Kingdom. Ecaterina E. Dumbrava's co-authors include Funda Meric‐Bernstam, Jordi Rodón, Sarina A. Piha‐Paul, Amber M. Johnson, Kavitha Balaji, Rashmi K. Murthy, Kanwal Raghav, Apostolia M. Tsimberidou, Siqing Fu and Timothy A. Yap and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ecaterina E. Dumbrava

99 papers receiving 1.0k citations

Peers

Countries citing papers authored by Ecaterina E. Dumbrava

Since Specialization

Citations

This map shows the geographic impact of Ecaterina E. Dumbrava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ecaterina E. Dumbrava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ecaterina E. Dumbrava more than expected).

Fields of papers citing papers by Ecaterina E. Dumbrava

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ecaterina E. Dumbrava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ecaterina E. Dumbrava. The network helps show where Ecaterina E. Dumbrava may publish in the future.

Co-authorship network of co-authors of Ecaterina E. Dumbrava

This figure shows the co-authorship network connecting the top 25 collaborators of Ecaterina E. Dumbrava. A scholar is included among the top collaborators of Ecaterina E. Dumbrava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ecaterina E. Dumbrava. Ecaterina E. Dumbrava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach 2025 ·Clinical Cancer Research ·Taiwo Adesoye, Ecaterina E. Dumbrava, Kanwal Raghav, Ayşegül A. Şahin, Hui Chen, Sunyoung S. Lee, Milind Javle, Shubham Pant, Omar Alhalabi, Xiuning Le, Vicente Valero, Paula R. Pohlmann, Funda Meric‐Bernstam	0
2	Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations 2025 ·ESMO Open ·Sarina A. Piha‐Paul, Chieh Tseng, Hai T. Tran, Aung Naing, Ecaterina E. Dumbrava, (unknown), Jordi Rodón, Timothy A. Yap, Kanwal Raghav, Senthil Damodaran, Xiao‐Feng Le, (unknown), (unknown), (unknown)	2
3	9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis 2025 ·ESMO Open ·(unknown), Jung Yong Hong, Maxime Chénard-Poirier, B-Y. Ryoo, Wan‐Teck Lim, (unknown), (unknown), Jens Samol, (unknown), (unknown), Ran Meng, Serena Masciari, Giovanni Abbadessa, (unknown), (unknown), Yan Zhang, Ecaterina E. Dumbrava	1
4	691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation 2024 ·Annals of Oncology ·Alison M. Schram, Gilberto Lopes, (unknown), Elisa Fontana, Thomas B. Karasic, (unknown), Patricia LoRusso, Vanesa Gregorc, (unknown), (unknown), Dominic Richardson, (unknown), Alexander I. Spira, Daniel Shao-Weng Tan, John A. Thompson, Dipesh Uprety, Marc Fellous, Yanguo Qin, Ecaterina E. Dumbrava	2
5	656P Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results 2024 ·Annals of Oncology ·(unknown), D-Y. Oh, Min‐Hee Ryu, Emiliano Calvo, (unknown), (unknown), (unknown), (unknown), Özlem Yıldırım, Serena Masciari, Gu Mi, (unknown), Pınar Kanlikilicer, (unknown), Faı̈za Rharbaoui, Giovanni Abbadessa, Ecaterina E. Dumbrava	0
6	A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Mohamed A. Gouda, (unknown), Aung Naing, Ecaterina E. Dumbrava, David S. Hong, Ying Yuan, Peiying Yang, Alan L. Myers, Yulong Liang, Jing Ping, Daniel D. Karp, Apostolia M. Tsimberidou, Jordi Rodón, Timothy A. Yap, Sarina A. Piha‐Paul, Funda Meric‐Bernstam, Siqing Fu	1
7	Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade. 2024 ·Journal of Clinical Oncology ·Goldy C. George, Sarina A. Piha‐Paul, Ecaterina E. Dumbrava, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Shubham Pant, (unknown), (unknown), Timothy A. Yap, Jordi Rodón, Funda Meric‐Bernstam, Charles S. Cleeland, Tito R. Mendoza, David S. Hong	0
8	Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 2024 ·Cancer Research ·Ecaterina E. Dumbrava, Fábio M. Iwamoto, Mark Agulnik, Mohammed Milhem, Anthony W. Tolcher, Rashmi Chugh, Michael J. Demeure, Alain C. Mita, (unknown), Mark S. Diamond, Beloo Mirakhur, (unknown), Aram Oganesian, (unknown), Harold Keer, Jason Taylor, Martin Sims, Andrea Biondo, Simone Jueliger, Alexander I. Spira	1
9	DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors. 2024 ·Journal of Clinical Oncology ·Ecaterina E. Dumbrava, Jonathan R. Thompson, (unknown), Ann Ranger, Ping Fan, Stanislav Katina, (unknown), Andrew Scott Paulson	1
10	Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing 2023 ·SHILAP Revista de lepidopterología ·(unknown), Molly S. Daniels, (unknown), Ecaterina E. Dumbrava, Ying Yuan, Keyur P. Patel, (unknown), (unknown), Chetna Wathoo, (unknown), (unknown), Wanlin Wang, Chacha Horombe, Milind Javle, Jordi Rodón, Timothy A. Yap, Banu Arun, Karen H. Lu, Funda Meric‐Bernstam	1
11	Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer 2023 ·SHILAP Revista de lepidopterología ·Ji Son, Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Jordi Rodón, Vivek Subbiah, Apostolia M. Tsimberidou, Timothy A. Yap, Michael Frumovitz, Amir A. Jazaeri, Pedro T. Ramírez, Shannon N. Westin, Ying Yuan, Funda Meric‐Bernstam, David S. Hong	1
12	738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors 2023 ·SHILAP Revista de lepidopterología ·Daniel J. Olson, Ecaterina E. Dumbrava, (unknown), (unknown), Syma Iqbal, Davendra Sohal, Maria Apostolopoulou, (unknown), Deyaa Adib, Benjamin L. Schlechter	1
13	Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies 2023 ·Cancer Research Communications ·Vivek Subbiah, Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón, Shubham Pant, Ecaterina E. Dumbrava, Siqing Fu, David S. Hong, (unknown), (unknown), (unknown), Jason Roszik, Juhee Song, Ying Yuan, Funda Meric‐Bernstam, Aung Naing	16
14	Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies 2023 ·Cancer ·(unknown), Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa, Siqing Fu, David S. Hong, Jordi Rodón, Timothy A. Yap, Apostolia M. Tsimberidou, Anas Alshawa, Ecaterina E. Dumbrava, (unknown), Juhee Song, Funda Meric‐Bernstam, Amir A. Jazaeri, Aung Naing	11
15	Discordance of HER2 Expression and/or Amplification on Repeat Testing 2023 ·Molecular Cancer Therapeutics ·Timothy P. DiPeri, Kathleen Kong, (unknown), Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha‐Paul, Ecaterina E. Dumbrava, Funda Meric‐Bernstam	7
16	859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial 2023 ·Annals of Oncology ·Loren S. Michel, Antonio Jimeno, Ammar Sukari, Thaddeus Beck, Joanne Chiu, (unknown), John Hilton, Antoine Hollebecque, Sylvie Zanetta, Jyoti D. Patel, Sabeen Mekan, Tzu‐Ching Wu, Ecaterina E. Dumbrava	8
17	Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification 2022 ·Journal of Clinical Oncology ·Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal, Thomas J. George, Ying Yuan, (unknown), Shannon N. Westin, (unknown), Ecaterina E. Dumbrava, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Jordi Rodón, Naoko Takebe, Karen H. Lu, Khandan Keyomarsi, Funda Meric‐Bernstam	50
18	728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors 2022 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), H-T. Arkenau, Ecaterina E. Dumbrava, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Shaad E. Abdullah, (unknown)	16
19	Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors 2022 ·ESMO Open ·(unknown), Geoffrey I. Shapiro, (unknown), Amit Mahipal, Jason S. Starr, Muhammad Furqan, Parminder Singh, (unknown), Leena Gandhi, Arnab Ghosh, (unknown), (unknown), (unknown), Eyal C. Attar, Mark M. Awad, Lakshmana Das, Ecaterina E. Dumbrava	34
20	Precision Oncology Decision Support: Current Approaches and Strategies for the Future 2018 ·Clinical Cancer Research ·Katherine C. Kurnit, Ecaterina E. Dumbrava, Beate C. Litzenburger, Yekaterina B. Khotskaya, Amber M. Johnson, Timothy A. Yap, Jordi Rodón, Jia Zeng, Md Abu Shufean, Ann M. Bailey, Nora Sánchez, Vijaykumar Holla, John Mendelsohn, Kenna M. Shaw, Elmer V. Bernstam, Gordon B. Mills, Funda Meric‐Bernstam	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact